Sangamo Therapeutics (SGMO.US): The 2024 Q1 financial report achieved revenue of US$481,000, with a previous value of US$158 million, with an expected value of US$6.65 million; earnings per share were -0.27 dollars, the previous value was $0.12, and the expected value was -0.21 dollars.
Sangamo Therapeutics(SGMO.US)：2024年Q1财报实现营收48.1万美元，前值为1.58亿美元，预期值为665万美元；每股收益为-0.27美元，前值为0.12美元，预期值为-0.21美元。
Sangamo Therapeutics (SGMO.US): The 2024 Q1 financial report achieved revenue of US$481,000, with a previous value of US$158 million, with an expected value of US$6.65 million; earnings per share were -0.27 dollars, the previous value was $0.12, and the e
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.